This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Armstrong, J. G. Articles by Peabody, A. M. Search for Related Content PubMed PubMed Citation Articles by Armstrong, J. G. Articles by Peabody, A. M.

Initial Clinical Experience with Vinglycinate Sulfate, a Molecular Modification of Vinblastine

Lilly Laboratory for Clinical Research, Marion County General Hospital, Indianapolis, Indiana

Vinglycinate sulfate (VGL), a derivative of vinblastine, has been employed in the treatment of 31 patients with malignant disease. Beneficial responses occurred in Hodgkin's disease, lymphosarcoma, bronchogenic carcinoma, and chondrosarcoma. Clinical evidence of lack of cross-resistance between VGL and both vinblastine sulfate and vincristine sulfate was encountered. Leukopenia was the dose-limiting toxicity. The dosage of VGL which produced benefit was approximately 10 times that of vinblastine.

Received 2/ 7/66. Accepted 8/24/66.